Venous thromboembolism in multiple sclerosis: a report of two cases with pulmonary embolism on dimethyl fumarate and available data from adverse event reporting systems. Time to include disease modifying drugs in the equation?

Clin Neurol Neurosurg. 2020 May:192:105726. doi: 10.1016/j.clineuro.2020.105726. Epub 2020 Feb 6.
No abstract available

Keywords: Dimethyl fumarate; Disease modifying treatment; Multiple sclerosis; Pulmonary embolism; Venous thromboembolism.

Publication types

  • Case Reports

MeSH terms

  • Adult
  • Adverse Drug Reaction Reporting Systems
  • Causality
  • Dimethyl Fumarate / therapeutic use*
  • Fatal Outcome
  • Female
  • Humans
  • Immunosuppressive Agents / therapeutic use*
  • Multiple Sclerosis, Relapsing-Remitting / drug therapy*
  • Multiple Sclerosis, Relapsing-Remitting / epidemiology*
  • Pulmonary Embolism / epidemiology*
  • Risk Factors
  • Venous Thromboembolism / epidemiology
  • Venous Thrombosis / epidemiology

Substances

  • Immunosuppressive Agents
  • Dimethyl Fumarate